Pyxis Oncology Company Insiders
| PYXS Stock | USD 1.12 0.05 4.67% |
Pyxis Oncology employs about 44 people. The company is managed by 10 executives with a total tenure of roughly 103 years, averaging almost 10.0 years of service per executive, having 4.4 employees per reported executive. Breaking down Pyxis Oncology's management performance can provide insight into the firm performance.
Pyxis |
Pyxis Oncology Management Team Effectiveness
The company has return on total asset (ROA) of (0.2477) % which means that it has lost $0.2477 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.6276) %, meaning that it created substantial loss on money invested by shareholders. Pyxis Oncology's management efficiency ratios could be used to measure how well Pyxis Oncology manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.53 in 2025. Return On Capital Employed is likely to drop to -0.67 in 2025. At this time, Pyxis Oncology's Non Currrent Assets Other are comparatively stable compared to the past year. Total Current Assets is likely to gain to about 137.5 M in 2025, whereas Net Tangible Assets are likely to drop slightly above 111 M in 2025.Common Stock Shares Outstanding is likely to drop to about 42.6 M in 2025. Net Loss is likely to gain to about (103.2 M) in 2025
Pyxis Oncology Workforce Comparison
Pyxis Oncology is rated below average in number of employees category among its peers. The total workforce of Health Care industry is at this time estimated at about 627. Pyxis Oncology holds roughly 44.0 in number of employees claiming about 7% of equities under Health Care industry.
Pyxis Oncology Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Pyxis Oncology insiders, such as employees or executives, is commonly permitted as long as it does not rely on Pyxis Oncology's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Pyxis Oncology insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Lewis-hall Freda C few days ago Acquisition by Lewis-hall Freda C of 66831 shares of Pyxis Oncology subject to Rule 16b-3 | ||
Kobayashi Ken over a week ago Acquisition by Kobayashi Ken of 443514 shares of Pyxis Oncology at 1.8 subject to Rule 16b-3 | ||
Jitendra Wadhane over two months ago Acquisition by Jitendra Wadhane of 150000 shares of Pyxis Oncology at 1.67 subject to Rule 16b-3 | ||
Connealy Pamela Ann over three months ago Acquisition by Connealy Pamela Ann of 5450 shares of Pyxis Oncology at 2.0 subject to Rule 16b-3 | ||
Feingold Jay over three months ago Acquisition by Feingold Jay of 209803 shares of Pyxis Oncology subject to Rule 16b-3 | ||
Dupont Jakob over six months ago Insider Trading | ||
Palani Santhosh over six months ago Insider Trading | ||
Palani Santhosh over six months ago Acquisition by Palani Santhosh of 6000 shares of Pyxis Oncology subject to Rule 16b-3 |
Pyxis Oncology Notable Stakeholders
A Pyxis Oncology stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Pyxis Oncology often face trade-offs trying to please all of them. Pyxis Oncology's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Pyxis Oncology's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| MBA MD | President CEO | Profile | |
| Balu Balasubramanian | Interim Officer | Profile | |
| Jan Pinkas | Chief Officer | Profile | |
| Pamela MBA | Chief Officer | Profile | |
| Charles Gombar | Senior Management | Profile | |
| MBA MBA | CoFounder Chairman | Profile | |
| MD FACP | Chief Officer | Profile | |
| Jitendra Wadhane | Senior Officer | Profile | |
| Martina BS | Interim Officer | Profile | |
| Stephen MBA | Senior Officer | Profile |
About Pyxis Oncology Management Performance
The success or failure of an entity such as Pyxis Oncology often depends on how effective the management is. Pyxis Oncology management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Pyxis management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Pyxis management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.50) | (0.53) | |
| Return On Capital Employed | (0.64) | (0.67) | |
| Return On Assets | (0.49) | (0.52) | |
| Return On Equity | (0.64) | (0.61) |
Please note, the imprecision that can be found in Pyxis Oncology's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Pyxis Oncology. Check Pyxis Oncology's Beneish M Score to see the likelihood of Pyxis Oncology's management manipulating its earnings.
Pyxis Oncology Workforce Analysis
Traditionally, organizations such as Pyxis Oncology use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Pyxis Oncology within its industry.Pyxis Oncology Manpower Efficiency
Return on Pyxis Oncology Manpower
| Revenue Per Employee | 367K | |
| Revenue Per Executive | 1.6M | |
| Net Loss Per Employee | 1.8M | |
| Net Loss Per Executive | 7.7M | |
| Working Capital Per Employee | 2.6M | |
| Working Capital Per Executive | 11.5M |
Additional Tools for Pyxis Stock Analysis
When running Pyxis Oncology's price analysis, check to measure Pyxis Oncology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pyxis Oncology is operating at the current time. Most of Pyxis Oncology's value examination focuses on studying past and present price action to predict the probability of Pyxis Oncology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pyxis Oncology's price. Additionally, you may evaluate how the addition of Pyxis Oncology to your portfolios can decrease your overall portfolio volatility.